While Eli Lilly LLY is a market leader in the GLP-1 segment, thanks to its tirzepatide medicines Mounjaro and Zepbound (for ...

Eli Lilly and Company (NYSE: LLY) announced today a planned investment of more than $1.2 billion to expand and modernize its ...

Eli Lilly LLY has been on an acquisition spree since the beginning of this year to bolster its pipeline, which should drive ...

While most of what the FDA laid out in a recent draft guidance on the assessment of overall survival in oncology clinical ...

Outside of the core registrational programs for these two important indications, we have several additional ongoing phase ...

The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising ...

Eli Lilly and Company has announced plans to invest more than $1.2 billion to expand and modernize its Lilly del Caribe manufacturing site in Puerto Rico.

Picking a date for a press conference in Puerto Rico in the middle of hurricane season can be risky business. | Eli Lilly has ...

A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. This story was originally published on BioPharma Dive. To ...

Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.

Now, let’s talk about the real contenders, okay. Let’s start with Eli Lilly, one I always said was going to get to trillion ...

The expansion forms part of Lilly’s broader $50bn capital investment programme to grow its US manufacturing and production ...